Aerie Pharmaceuticals reported a net loss of $51.5 million, or $1.14 per share, in the fourth quarter of 2018 compared with a net loss of $58.5 million, or $1.60 per share, in 2017’s fourth quarter.
The loss includes $14.1 million of gross profit and $66 million in operating expenses compared with no gross profit and $60.3 million in operating expenses in the fourth quarter of 2017, according to a press release.
For the full year, net loss totaled $232.6 million compared with $145.1 million in 2017.
Revenues for Rhopressa (netarsudil (Read more...)
Uncategorized